Comparing the current results to its competitors, Acelyrin Inc reported Revenue decrease in the 1 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 3.8 %, recorded in the same quarter.
Acelyrin Inc 's Comment on Competition and Industry Peers
The competitive landscape includes challenges concerning patent validity and enforceability, potential design-arounds by competitors, and infringement claims that may require costly and time-consuming defense. Success relies on maintaining patent protection, trade secret confidentiality, and licenses for third-party intellectual property.
October 16, 2024
In a significant stride towards advancing the treatment landscape for Thyroid Eye Disease (TED), ACELYRIN, INC. has officially announced the formation of a Scientific and Patient Advisory Board. This coalition is comprised of prominent voices within the realms of clinical research and patient advocacy, who will provide vital strategic input as the company progresses through its Phase 2 clinical trial of lonigutamab, a promising therapeutic candidate for TED. The Need for Expertise in TED Thyroid Eye Disease, commonly associated with Graves disease, is a debilitating condition that can lead to a multitude of complications, including vision loss and cosmetic deformities. As the understanding of TED evolves, t...
September 19, 2024
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and sinus tract formation. The condition can significantly impact patients quality of life due to pain, discomfort, and psychosocial distress. While various treatment options exist, there remains a need for more effective therapeutic agents for moderate-to-severe cases. Recently, Acelyrin, Inc. announced promising results from a Phase 3 clinical trial evaluating izokibep, a novel therapeutic agent, in patients with moderate-to-severe HS. Study Overview and Presentation On September 19, 2024, Acelyrin, Inc. revealed that positive results from their global Phase 3 clinical trial of izokibep will...
September 10, 2024
CSIMarket.com Date: 12th October 2023 In a most auspicious development for the field of ophthalmic medicine, ACELYRIN, INC. renowned for its relentless innovation in biopharmaceuticals, hath declared the forthcoming unveiling of promising proof-of-concept data emerging from their Phase 1/2 clinical trial of the novel therapeutic agent Lonigutamab, designed for the subcutaneous treatment of Thyroid Eye Disease (TED). This prestigious information is to be presented at the forthcoming 42nd Annual Meeting of the European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS).This discourse shall feature a rapid-fire oral presentation, whereupon esteemed researchers will elucidate the efficacy, safe...
May 29, 2024
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024Thyroid eye disease (TED), also known as Graves ophthalmopathy, is an autoimmune condition that affects thousands of individuals worldwide. It is characterized by inflammation and swelling in the tissues around the eyes, causing eye bulging, double vision, and even vision loss in severe cases. Patients suffering from TED often experience a significant impact on their quality of life, both physically and emotionally.In a groundbreaking development, ACELYRIN, INC. has recently announced the release of Phase 1/2 proof-of-concept data for their revolutionary drug, Lonigutamab. Lon...
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
Ventyx Biosciences Inc is a biotechnology company that follows a research and development-focused business model. It aims to develop innovative biopharmaceutical products and therapeutic solutions by leveraging its expertise in various fields such as genetic engineering, drug discovery, and clinical trials. The company seeks to form strategic partnerships and licensing agreements to accelerate the commercialization of its products.
Sources:
Acelyrin Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Acelyrin Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
